Navigation Links
Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
Date:3/3/2008

lize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase Ib pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include a breast cancer trial of bavituximab in combination with docetaxel that is currently enrolling patients, a breast cancer protocol assessing bavituximab in combination with carboplatin plus paclitaxel and a non-small cell lung cancer protocol assessing bavituximab in combination with carboplatin and paclitaxel. Bavituximab is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

The study, "Vascular Imaging of Solid Tumors in Rats with a Radioactive Arsenic-Labeled Antibody that Binds Exposed Phosphatidylserine," by Marc Jennewein, Matthew A. Lewis, Dawen Zhao, Edward Tsyganov, Nikolai Slavine, Jin He, Linda Watkins, Vikram D. Kodibagkar, Sean O'Kelly, Padmakar Kulkarni, Peter P. Antich, Alex Hermanne, Frank Rosch, Ralph P. Mason and Philip E. Thorpe, appears in the March 1, 2008 issue of Clinical Cancer Research.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
3. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
4. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
5. Research by Case Western Reserve University, VA earns cover of prestigious science publication
6. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
7. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
8. Industry Executives Finding Value in Shift of Scientific Publications
9. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
10. Nventa announces publication of HspE7 data
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June 24 international ... Adult Stem Cell Technology Center, LLC ( ASCTC ) ... unique property of adult tissue stem cells. His ... the Past, Important for the Future,” embodied the essence ... the address at the 4th World Congress on Cell ...
(Date:12/24/2014)... 2014 The report provides ... its definition, classification, application and industry overview. ... process, and product cost structure. Production is ... analysis also covers upstream raw materials, equipment, ... trend and proposals. In the end, the ...
(Date:12/24/2014)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China ... plasma-based biopharmaceutical company in China ... Taibang Biological Products Co. Ltd., has received Good ... and Drug Administration (the "CFDA") for its new ... the Company,s public filings, the CFDA inspected this ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... ... listed below, ST. LOUIS, June 13 ETHEX Corporation announced ... mg extended release tablets, and specific lots of morphine,sulfate 30 mg ... oversized tablets. Oversized tablets may contain as,much as two times the ...
... Conn., June 13 Alexion,Pharmaceuticals, Inc. (Nasdaq: ... President and Chief Financial Officer of Alexion,Pharmaceuticals, will ... Stock,Conference in Chicago at 9:10 a.m., local time ... An audio webcast of Mr. Sinha,s remarks will ...
... 13 Best Practices, LLC,s latest,benchmarking study explains ... CI operations while working within defined,guidelines., Particular ... is being,collected, and how CI groups work within ... collection that are in the best interests of,the ...
Cached Biology Technology:ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 2ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 3ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 4Pharmaceutical Competitive Intelligence Excellence: Optimizing Data Collection with Approved Guidelines 2
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... available amount of fossil fuels is limited and their ... The generation of fuels from biomass as an alternative ... Chemie , Johannes A. Lercher and his team at ... catalytic process that allows the effective conversion of biopetroleum ...
... KAN. -- A Kansas State University graduate student sees the ... Smith, master,s student in civil engineering, Independence, Mo., is working ... to improve the quality of unpaved roads throughout Kansas. ... in Kansas are unpaved, Smith said. "One of the ...
... advancing field of tissue injury and repair has an ... will report the latest research findings, innovative wound care ... skin and tissue regeneration to optimize patient outcomes. The ... is an Official Publication of the Wound Healing ...
Cached Biology News:Algae for your fuel tank 2The path less traveled: Research is driving solutions to improve unpaved roads 2The path less traveled: Research is driving solutions to improve unpaved roads 3New publication fosters improved wound care for ulcers, limb salvage, burns, trauma, and more 2
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb...
Anti-MT3-MMP Membrane-Type Metalloproteinase-3; propeptide domain; rabbit host...
Biology Products: